KALA BIO, Inc. (NASDAQ:KALA) Given Consensus Recommendation of "Buy" by Analysts

Key Points

• KALA BIO, Inc. has received a consensus rating of "Buy" from five analysts, with target prices averaging $17.25.
• Insider transactions revealed a director sold 13,227 shares for a total of $53,040, reducing their ownership by 4.87%.
• The company's stock has shown significant growth, with a 400% increase over the past month, reaching a price of $14.55.

KALA BIO, Inc. (NASDAQ:KALA - Get Free Report) has been given a consensus rating of "Buy" by the five analysts that are currently covering the company, Marketbeat.com reports. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $17.25.

Several research analysts recently issued reports on KALA shares. Lifesci Capital upgraded shares of KALA BIO to a "strong-buy" rating in a research report on Wednesday, September 3rd. Wall Street Zen cut shares of KALA BIO from a "hold" rating to a "sell" rating in a research report on Saturday, August 9th. Oppenheimer reaffirmed an "outperform" rating and issued a $15.00 target price on shares of KALA BIO in a research report on Monday, June 2nd. Mizuho started coverage on shares of KALA BIO in a research report on Monday. They set an "outperform" rating and a $30.00 price target for the company. Finally, LADENBURG THALM/SH SH started coverage on shares of KALA BIO in a research note on Friday, July 11th. They set a "buy" rating and a $12.00 price objective for the company.

Insider Activity at KALA BIO

In other news, Director Mark T. Iwicki sold 13,227 shares of KALA BIO stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $4.01, for a total value of $53,040.27. Following the completion of the sale, the director directly owned 258,433 shares in the company, valued at $1,036,316.33. The trade was a 4.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders have sold 30,678 shares of company stock valued at $123,019 in the last three months. Insiders own 8.32% of the company's stock.

Institutional Trading of KALA BIO

A number of large investors have recently made changes to their positions in the stock. XTX Topco Ltd bought a new stake in KALA BIO during the second quarter valued at approximately $62,000. Geode Capital Management LLC lifted its holdings in shares of KALA BIO by 2.8% in the second quarter. Geode Capital Management LLC now owns 56,367 shares of the company's stock worth $268,000 after buying an additional 1,534 shares in the last quarter. AIGH Capital Management LLC lifted its holdings in shares of KALA BIO by 52.8% in the second quarter. AIGH Capital Management LLC now owns 300,000 shares of the company's stock worth $1,428,000 after buying an additional 103,650 shares in the last quarter. Woodline Partners LP purchased a new position in shares of KALA BIO in the first quarter worth $1,483,000. Finally, ADAR1 Capital Management LLC increased its position in KALA BIO by 35.7% in the first quarter. ADAR1 Capital Management LLC now owns 298,955 shares of the company's stock worth $1,713,000 after purchasing an additional 78,582 shares during the last quarter. 24.61% of the stock is currently owned by institutional investors.

KALA BIO Stock Performance

KALA BIO stock opened at $14.55 on Monday. The firm's 50 day simple moving average is $7.78 and its 200 day simple moving average is $5.79. The company has a current ratio of 2.10, a quick ratio of 2.10 and a debt-to-equity ratio of 3.19. The firm has a market capitalization of $102.14 million, a PE ratio of -2.14 and a beta of -1.82. KALA BIO has a 1-year low of $2.92 and a 1-year high of $15.80.

KALA BIO (NASDAQ:KALA - Get Free Report) last posted its quarterly earnings data on Friday, August 8th. The company reported ($1.71) earnings per share for the quarter, beating the consensus estimate of ($1.82) by $0.11. As a group, analysts expect that KALA BIO will post -10.84 earnings per share for the current fiscal year.

KALA BIO Company Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.